A novel pan-PI3K inhibitor KTC1101 synergizes with anti-PD-1 therapy by targeting tumor suppression and immune activation.
Peng X, Huang X, Lulu TB, Jia W, Zhang S, Cohen L, Huang S, Fan J, Chen X, Liu S, Wang Y, Wang K, Isoyama S, Dan S, Wang F, Zhang Z, Elkabets M, Kong D.
Peng X, et al. Among authors: dan s.
Mol Cancer. 2024 Mar 14;23(1):54. doi: 10.1186/s12943-024-01978-0.
Mol Cancer. 2024.
PMID: 38486218
Free PMC article.